TGFB1 and neoplasm: In agreement, an anti-TGFβ blocking therapeutic monoclonal antibody 1D1146 severely impaired tumor growth of TE11 xenograft tumors as well as OCTT2 head and neck SCC patient-derived xenografts (PDXs) (Fig. 4a).